Clinical and nutritional-inflammatory biomarkers-based nomogram predicts survival in recurrent or metastatic cervical cancer treated with immune checkpoint inhibitors.

ABSTRACT:

Background

Immunotherapy offers potential benefits for recurrent or metastatic cervical cancer (R/M CC), yet personalized predictive tools are essential for optimizing treatment. This study aims to develop a nomogram integrating nutritional-inflammatory biomarkers and clinical features to predict survival in R/M CC patients undergoing immune checkpoint inhibitor (ICI) therapy.

Patients and methods

We retrospectively analyzed 98 R/M CC patients treated with ICIs. Overall survival (OS) was the primary endpoint. Demographic characteristics and peripheral blood biomarkers before and after ICI treatment were collected. Univariate analysis screened potential variables, followed by LASSO regression to select key biomarkers and compute the Risk-Score. Prediction models combining cli

SUBMITTER: Yan Q 

PROVIDER: S-EPMC12777797 | biostudies-literature | 2026 Dec

REPOSITORIES: biostudies-literature